Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Targeting AATF reprograms the tumor microenvironment and suppresses hepatocellular carcinoma via MIR100HG–TGF-β signaling

View through CrossRef
Abstract Hepatocellular carcinoma (HCC), a leading cause of cancer death, has a dynamic and heterogeneous tumor microenvironment (TME) that drives progression and therapeutic resistance. We previously elucidated that apoptosis antagonizing transcription factor (AATF) drives angiogenesis in HCC. However, its role in TME remains unexplored. We employed an orthotopic xenograft mouse model, implanting human HCC cells into the liver, and achieved liver-specific silencing via tail vein injection of AAV8 carrying mouse-specific siAATF or siControl. Histological, biochemical, and molecular analyses, combined with whole-genome transcriptomics mapped to mouse and human genomes, were used to study TME and tumor compartments separately. Silencing of AATF in the TME significantly reduced tumor growth compared with controls. Furthermore, AATF loss disrupted key processes in TME, including inflammation, immune response, angiogenesis, and extracellular matrix remodeling. Mechanistically, TGF-β signaling was significantly suppressed in the TME, thereby affecting tumor cell cycle and metabolic activity, ultimately leading to tumor regression. The long noncoding RNA (lncRNA) analysis identified MIR100HG as a key downstream regulator of AATF in the TGF-β signaling pathway. These findings expand the oncogenic role of AATF to include regulation of the TME via the AATF–MIR100HG–TGF-β axis, highlighting its potential as a therapeutic target in HCC.
Title: Targeting AATF reprograms the tumor microenvironment and suppresses hepatocellular carcinoma via MIR100HG–TGF-β signaling
Description:
Abstract Hepatocellular carcinoma (HCC), a leading cause of cancer death, has a dynamic and heterogeneous tumor microenvironment (TME) that drives progression and therapeutic resistance.
We previously elucidated that apoptosis antagonizing transcription factor (AATF) drives angiogenesis in HCC.
However, its role in TME remains unexplored.
We employed an orthotopic xenograft mouse model, implanting human HCC cells into the liver, and achieved liver-specific silencing via tail vein injection of AAV8 carrying mouse-specific siAATF or siControl.
Histological, biochemical, and molecular analyses, combined with whole-genome transcriptomics mapped to mouse and human genomes, were used to study TME and tumor compartments separately.
Silencing of AATF in the TME significantly reduced tumor growth compared with controls.
Furthermore, AATF loss disrupted key processes in TME, including inflammation, immune response, angiogenesis, and extracellular matrix remodeling.
Mechanistically, TGF-β signaling was significantly suppressed in the TME, thereby affecting tumor cell cycle and metabolic activity, ultimately leading to tumor regression.
The long noncoding RNA (lncRNA) analysis identified MIR100HG as a key downstream regulator of AATF in the TGF-β signaling pathway.
These findings expand the oncogenic role of AATF to include regulation of the TME via the AATF–MIR100HG–TGF-β axis, highlighting its potential as a therapeutic target in HCC.

Related Results

Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
TACE inhibition: a promising therapeutic intervention against AATF‐mediated steatohepatitis to hepatocarcinogenesis
TACE inhibition: a promising therapeutic intervention against AATF‐mediated steatohepatitis to hepatocarcinogenesis
Metabolic dysfunction‐associated steatohepatitis‐driven hepatocellular carcinoma (MASH‐HCC) is a global clinical challenge for which there is a limited understanding of disease pat...
AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma
AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma
Background and aims Angiogenesis is a key factor in the growth and metastasis of hepatic tumors and thus a potential therapeutic target in hepatocellular carcin...
AATF Inhibition Exerts Antiangiogenic Effects Against Human Hepatocellular Carcinoma
AATF Inhibition Exerts Antiangiogenic Effects Against Human Hepatocellular Carcinoma
Abstract Hepatocellular carcinoma (HCC), a highly fatal cancer with a mortality rate proportional to its incidence, continues to pose a global health care challenge. Angiog...
AATF Inhibition Exerts Antiangiogenic Effects Against Human Hepatocellular Carcinoma
AATF Inhibition Exerts Antiangiogenic Effects Against Human Hepatocellular Carcinoma
ABSTRACT Hepatocellular carcinoma (HCC), a highly fatal cancer with a mortality rate proportional to its incidence, continues to pose a global health care challenge...

Back to Top